Additional file 1: of Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients

Gianotti, Nicola; Poli, Andrea; Nozza, Silvia; Galli, Laura; Galizzi, Nadia; Ripa, Marco; Merli, Marco; Carbone, Alessia; Spagnuolo, Vincenzo; Lazzarin, Adriano; Castagna, Antonella

doi:10.6084/m9.figshare.c.3932917_D1.v1

12879_2017_2831_MOESM1_ESM.docx (12.46 kB)

Additional file 1: of Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients

journal contribution

posted on 2017-11-16, 05:00 authored by Nicola Gianotti, Andrea Poli, Silvia Nozza, Laura Galli, Nadia Galizzi, Marco Ripa, Marco Merli, Alessia Carbone, Vincenzo Spagnuolo, Adriano Lazzarin, Antonella Castagna

Specific PIs and NNRTIs ongoing at baseline. (DOCX 12Â kb)

History

Usage metrics

Keywords

Rilpivirine Raltegravir Elvitegravir/cobicistat Dolutegravir Non-nucleoside reverse transcriptase inhibitors Integrase inhibitors Switch regimen Residual viremia Virological suppression

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 1: of Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients

History

Usage metrics

Categories

Keywords

Licence

Exports